✨ Medicines and Research Notices
NEW ZEALAND GAZETTE, No. 61 — 7 JULY 2016
This notice supersedes and revokes the following notices:
-
Research, Science, and Technology Funding Subject to a Separate Decision-making Process published in the New Zealand Gazette, 6 June 2013, No. 72, page 1918;
-
Amendment to the Notice—Research, Science, and Technology Funding Subject to a Separate Decision-making Process published in the New Zealand Gazette, 23 October 2014, Issue No. 130, Notice No. 2014-go6467.
-
Amendment to the Notice—Research, Science, and Technology Funding Subject to a Separate Decision-making Process published in the New Zealand Gazette, 24 July 2014, No. 79, page 2198; and
-
Research, Science, and Technology Funding Subject to a Separate Decision-making Process published in the New Zealand Gazette, 23 June 2016, Issue No 58, Notice No. 2016-go3570.
This notice comes into effect on 1 July 2016.
Dated at Wellington this 28th day of June 2016.
Hon STEVEN JOYCE, Minister of Science and Innovation.
2016-go3833
Consent to the Distribution of New Medicines
Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines set out in the Schedule hereto:
Schedule
Product:
Active Ingredient:
Clindamycin phosphate 197.88mg/mL equivalent to clindamycin 150mg/mL
Dosage Form:
Solution for injection
New Zealand Sponsor:
Mylan New Zealand Limited
Manufacturer:
Mylan Teoranta, Kilroe East, Galway, Ireland
Product:
Clindamycin Mylan
Product:
Active Ingredient:
Paracetamol 10mg/mL
Dosage Form:
Solution for injection
New Zealand Sponsor:
Fresenius Kabi New Zealand Limited
Manufacturers:
Fresenius Kabi Austria GmbH, Graz, Austria
Fresenius Kabi France, Louviers, France
Fresenius Kabi Norge AS, Halden, Norway
Fresenius Kabi Deutschland GmbH, Friedberg, Germany
Product:
Paracetamol Kabi
Product:
Active Ingredients:
Brimonidine tartrate 2mg/mL
Brinzolamide 10mg/mL
Dosage Form:
Eye drops, suspension
New Zealand Sponsor:
Alcon Laboratories
Manufacturer:
SA Alcon Couvreur NV, Puurs, Belgium
Product:
Simbrinza
Product:
Active Ingredient:
Tranexamic acid 100mg/mL
Dosage Form:
Solution for injection
New Zealand Sponsor:
AFT Pharmaceuticals Limited
Manufacturer:
Labiana Pharmaceuticals SL, Barcelona, Spain
Product:
Tranexamic-AFT
Dated this 30th day of June 2016.
CHRIS JAMES, Acting Group Manager, Medsafe, Ministry of Health (pursuant to delegation given by the Minister of Health on 11 September 2013).
2016-go3847
Consent to the Distribution of New Medicines
63
Next Page →
NZ Gazette 2016, No 61
✨ LLM interpretation of page content
🎓
Research, Science, and Technology Funding Subject to a Separate Decision-making Process
(continued from previous page)
🎓 Education, Culture & Science28 June 2016
Research, Science, and Technology, Funding, Decision-making Process
- Hon Steven Joyce, Minister of Science and Innovation
🏥 Consent to the Distribution of New Medicines
🏥 Health & Social Welfare30 June 2016
Medicines, Distribution, Clindamycin, Paracetamol, Brimonidine, Tranexamic acid
- Chris James, Acting Group Manager, Medsafe, Ministry of Health